Get the Stockscreener App
3.90
0.26%
0.010
After Hours:
3.90
Insight Molecular Diagnostics Inc stock is traded at $3.90, with a volume of 16,541.
It is up +0.26% in the last 24 hours and up +26.62% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$3.89
Open:
$3.9
24h Volume:
16,541
Relative Volume:
0.48
Market Cap:
$111.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.90%
1M Performance:
+26.62%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.75
$3.97
1-Week Range:
$3.30
$3.97
52-Week Range:
$2.33
$3.97
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.90 | 111.33M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFsJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliable - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy By Investing.com - Investing.com Nigeria
Imdx reports kidney transplant patient achieved 'immune reset' with novel therapy and GraftAssure monitoring - MarketScreener
Molecular Diagnostics Market Analysis: Trends, Opportunities, and Forecast - newstrail.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock benefits from AI revolutionJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Insight Molecular Diagnostics Extends Executive Employment Agreement - TipRanks
Insight Molecular Diagnostics grants stock options to executives and amends employment agreement - Investing.com
What analysts say about Insight Molecular Diagnostics Inc 7OC0 stockContrarian Investment Ideas & Stay Invested. Stay Smart. - earlytimes.in
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Autoimmune Disease Diagnostics Market Size Report, 2034 - Global Market Insights Inc.
Why Insight Molecular Diagnostics Inc. (7OC0) stock fits value portfoliosQuarterly Market Review & Smart Allocation Stock Tips - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView
Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus
Analysts’ Top Healthcare Picks: CareDx (CDNA), Semler Scientific (SMLR) - The Globe and Mail
Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando - MarketScreener
Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow
North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc. Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - MarketScreener
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewswire
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - The Manila Times
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Insight Molecular Diagnostics Inc Stock (IMDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SMITH PATRICK W | 10% Owner |
Feb 07 '25 |
Buy |
2.05 |
1,077,600 |
2,209,080 |
2,872,671 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 06 '25 |
Buy |
2.05 |
5,165,695 |
10,589,675 |
11,410,100 |
| SMITH PATRICK W | 10% Owner |
Jan 31 '25 |
Buy |
2.01 |
890 |
1,789 |
1,795,046 |
| SMITH PATRICK W | 10% Owner |
Feb 04 '25 |
Buy |
2.02 |
25 |
50 |
1,795,071 |
| SMITH PATRICK W | 10% Owner |
Jan 29 '25 |
Buy |
2.01 |
3,880 |
7,799 |
1,793,838 |
| SMITH PATRICK W | 10% Owner |
Jan 30 '25 |
Buy |
2.01 |
318 |
639 |
1,794,156 |
| SMITH PATRICK W | 10% Owner |
Jan 14 '25 |
Buy |
2.15 |
10,386 |
22,323 |
1,789,958 |
| SMITH PATRICK W | 10% Owner |
Jan 13 '25 |
Buy |
2.08 |
5,669 |
11,792 |
1,779,572 |
| SMITH PATRICK W | 10% Owner |
Dec 26 '24 |
Buy |
2.13 |
90,219 |
192,166 |
1,773,903 |
| Arno Andrew | Director |
Dec 26 '24 |
Buy |
2.11 |
12,500 |
26,350 |
81,554 |
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):